Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) inhibitor cabozantinib

Cabozantinib (XL184) is a small molecule tyrosine kinase receptor inhibitor, which targets c-Met and VEGFR2. Cabozantinib has been approved by the Food and Drug Administration to treat advanced medullary thyroid cancer and renal cell carcinoma. In the present study, we evaluated the ability of caboz...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacol Res
Main Authors: Zhang, Guan-Nan, Zhang, Yun-Kai, Wang, Yi-Jun, Barbuti, Anna Maria, Zhu, Xi-Jun, Yu, Xin-Yue, Wen, Ai-Wen, Wurpel, John N.D., Chen, Zhe-Sheng
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5392419/
https://ncbi.nlm.nih.gov/pubmed/28131876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.phrs.2017.01.024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados